CO5611098A2 - Composicion para inhalacion - Google Patents
Composicion para inhalacionInfo
- Publication number
- CO5611098A2 CO5611098A2 CO04071996A CO04071996A CO5611098A2 CO 5611098 A2 CO5611098 A2 CO 5611098A2 CO 04071996 A CO04071996 A CO 04071996A CO 04071996 A CO04071996 A CO 04071996A CO 5611098 A2 CO5611098 A2 CO 5611098A2
- Authority
- CO
- Colombia
- Prior art keywords
- inhalation
- composition
- formoterol
- budesonide
- formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
- Networks Using Active Elements (AREA)
Abstract
1.- Una composición farmacéutica que comprende formoterol, budesonida, HFA 227, PVP y PEG.2.- Una formulación de acuerdo con la reivindicación 1, caracterizado en que la PVP está presente desde aproximadamente 0.0005 a aproximadamente 0.05% p/p y el PEG está presente desde aproximadamente 0.05 a aproximadamente 0.35% p/p.3.- Una composición farmacéutica de acuerdo con la reivindicación 1 ó 2, en la cual la PVP es PVP K25.4.- Una composición farmacéutica de acuerdo con la reivindicación 1 a 3, en la cual la PVP está presente en una cantidad de 0.001% p/p.5.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 4, en la cual el PEG es PEG 1000.6.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 5, en la cual el PEG está presente en una cantidad de 0.3% p/p.7.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 6, en la cual el formoterol está en la forma de su sal de fumarato dihidratado. 8.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 7, en la cual el formoterol está en la forma del enantiómero R, R sencillo.9.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 8, en la cual el segundo ingrediente activo es el epímero 22R de budesonida.10.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 9 para el uso en el tratamiento o profilaxis de un trastorno respiratorio.11.- Una composición farmacéutica de acuerdo con cualquiera de las reivindicaciones 1 a 9 para el uso en el tratamiento o profilaxis de asma, rinitis o COPD.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200312A SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Novel composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5611098A2 true CO5611098A2 (es) | 2006-02-28 |
Family
ID=20286853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO04071996A CO5611098A2 (es) | 2002-02-01 | 2004-07-27 | Composicion para inhalacion |
Country Status (28)
| Country | Link |
|---|---|
| US (8) | US7759328B2 (es) |
| EP (2) | EP2036549B1 (es) |
| JP (2) | JP2005521663A (es) |
| KR (2) | KR20090125857A (es) |
| CN (1) | CN1287774C (es) |
| AT (2) | ATE423552T1 (es) |
| AU (1) | AU2003206289B2 (es) |
| BR (1) | BR0307193A (es) |
| CA (1) | CA2474479C (es) |
| CO (1) | CO5611098A2 (es) |
| CY (2) | CY1109030T1 (es) |
| DE (2) | DE60326320D1 (es) |
| DK (2) | DK1474117T3 (es) |
| ES (2) | ES2321180T3 (es) |
| HK (1) | HK1126684A1 (es) |
| IL (1) | IL163160A (es) |
| IS (2) | IS7360A (es) |
| MX (1) | MXPA04007295A (es) |
| NO (1) | NO337006B1 (es) |
| NZ (1) | NZ534452A (es) |
| PL (1) | PL211836B1 (es) |
| PT (2) | PT2036549E (es) |
| RU (1) | RU2301673C2 (es) |
| SE (1) | SE0200312D0 (es) |
| SI (2) | SI2036549T1 (es) |
| UA (1) | UA79445C2 (es) |
| WO (1) | WO2003063842A1 (es) |
| ZA (1) | ZA200406086B (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| DK1845994T3 (da) * | 2005-02-11 | 2009-05-04 | Argenta Discovery Ltd | Kombination af methylxanthinforbindelser og steroider til at behandle kroniske luftvejssygdomme |
| US9084799B2 (en) | 2005-02-11 | 2015-07-21 | Pulmagen Therapeutics (Synergy) Limited | Inhaled combination therapy |
| DE102006053374A1 (de) * | 2006-02-09 | 2007-08-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz |
| GB0604141D0 (en) * | 2006-03-01 | 2006-04-12 | Arrow Int Ltd | Nebulizer formulation |
| GB0712454D0 (en) * | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| US20130160761A1 (en) * | 2008-11-04 | 2013-06-27 | Cipla Limited | Pharmaceutical Aerosol Composition |
| NZ574666A (en) * | 2009-02-05 | 2009-04-30 | Nexus6 Ltd | A medicament inhaler holder that uses optical means to count and display the number of doses used |
| WO2010112358A2 (de) | 2009-03-31 | 2010-10-07 | Boehringer Ingelheim International Gmbh | Verfahren zur beschichtung einer oberfläche eines bauteils |
| JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
| JP5658268B2 (ja) | 2009-11-25 | 2015-01-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| EA026241B1 (ru) | 2009-11-25 | 2017-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Распылитель |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| EP3871676A1 (en) * | 2010-07-16 | 2021-09-01 | Cipla Limited | Pharmaceutical compositions comprising r(+) budesonide and arformoterol |
| CN103052378A (zh) * | 2010-08-03 | 2013-04-17 | 奇斯药制品公司 | 包含磷酸二酯酶抑制剂的药物制剂 |
| EP2618818A4 (en) * | 2010-09-22 | 2014-10-29 | Map Pharmaceuticals Inc | CORTICOSTEROID PARTICLES AND METHOD FOR PRODUCING THE SAME |
| US20120204871A1 (en) | 2011-02-10 | 2012-08-16 | Julio Cesar Vega | Stable, non-corrosive formulations for pressurized metered dose inhalers |
| TWI399202B (zh) * | 2011-03-17 | 2013-06-21 | Intech Biopharm Ltd | 製備用於治療呼吸道疾病之定量噴霧吸入劑的製程方法 |
| WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| US9241904B1 (en) | 2011-08-19 | 2016-01-26 | Intech Biopharm Ltd. | Method for preparing metered dose sprayed inhaler for treating respiratory disease |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
| EP2835146B1 (en) | 2013-08-09 | 2020-09-30 | Boehringer Ingelheim International GmbH | Nebulizer |
| GB201321712D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| GB201321717D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| EP3139984B1 (en) | 2014-05-07 | 2021-04-28 | Boehringer Ingelheim International GmbH | Nebulizer |
| DK3139979T3 (da) | 2014-05-07 | 2023-10-09 | Boehringer Ingelheim Int | Enhed, forstøver og fremgangsmåde |
| NZ724449A (en) | 2014-05-07 | 2022-01-28 | Boehringer Ingelheim Int | Nebulizer and container |
| US20170189329A1 (en) | 2014-07-29 | 2017-07-06 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| BR122020022602B1 (pt) | 2015-12-04 | 2024-03-05 | Mexichem Fluor S.A. De C.V. | Composição farmacêutica |
| CN106581010B (zh) * | 2016-12-28 | 2019-03-05 | 四川普锐特医药科技有限责任公司 | 一种气溶胶制剂及定量吸入气雾剂 |
| AU2018318123B2 (en) | 2017-08-15 | 2024-07-25 | Nephron Pharmaceuticals Corporation | Aqueous nebulization composition |
| AU2019287541A1 (en) | 2018-06-14 | 2021-01-21 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
| JP7402631B2 (ja) | 2018-08-27 | 2023-12-21 | 帝人株式会社 | 極細炭素繊維混合物、その製造方法、及び炭素系導電助剤 |
| CN109464429B (zh) * | 2018-12-13 | 2021-04-27 | 上海方予健康医药科技有限公司 | 一种吸入压力定量气雾剂药物组合物及其制备方法 |
| CN112137957B (zh) | 2019-06-26 | 2022-07-29 | 长风药业股份有限公司 | 一种药用吸入气雾剂及其制备方法 |
| CN112972384B (zh) * | 2019-12-02 | 2022-03-18 | 长风药业股份有限公司 | 一种格隆溴铵和茚达特罗原料药微粉混合物的制备方法 |
| CN117357485B (zh) * | 2023-11-01 | 2024-09-24 | 山东京卫制药有限公司 | 一种改良的可吸入的载体颗粒及应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL103238A (en) | 1991-09-25 | 1995-07-31 | Fisons Plc | Pressed aerosol preparations |
| US6123924A (en) * | 1991-09-25 | 2000-09-26 | Fisons Plc | Pressurized aerosol inhalation compositions |
| CZ288032B6 (cs) | 1991-12-18 | 2001-04-11 | Aktiebolaget Astra | Farmaceutický prostředek pro podání inhalací |
| DE19536902A1 (de) * | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
| ES2178015T3 (es) * | 1996-11-11 | 2002-12-16 | Sepracor Inc | Procedimiento de preparacion de isomeros de formoterol opticamente puros. |
| SE9703407D0 (sv) * | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| US6309623B1 (en) * | 1997-09-29 | 2001-10-30 | Inhale Therapeutic Systems, Inc. | Stabilized preparations for use in metered dose inhalers |
| SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| NZ509328A (en) | 1998-07-24 | 2002-11-26 | Jago Res A | Medicinal aerosol formulations |
| US6004537A (en) * | 1998-12-18 | 1999-12-21 | Baker Norton Pharmaceuticals, Inc. | Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol |
| SE9900834D0 (sv) | 1999-03-09 | 1999-03-09 | Astra Ab | Novel combination |
| PE20011227A1 (es) * | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0009584D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Pharmaceutical compositions |
| GB0012260D0 (en) * | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel composition |
| GB0016876D0 (en) | 2000-07-11 | 2000-08-30 | Astrazeneca Ab | Novel formulation |
| US20030018019A1 (en) * | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
| SE0200312D0 (sv) * | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
-
2002
- 2002-02-01 SE SE0200312A patent/SE0200312D0/xx unknown
-
2003
- 2003-01-29 PT PT08166881T patent/PT2036549E/pt unknown
- 2003-01-29 DK DK03703575T patent/DK1474117T3/da active
- 2003-01-29 PL PL372118A patent/PL211836B1/pl unknown
- 2003-01-29 AU AU2003206289A patent/AU2003206289B2/en not_active Expired
- 2003-01-29 BR BR0307193-6A patent/BR0307193A/pt not_active Application Discontinuation
- 2003-01-29 CA CA2474479A patent/CA2474479C/en not_active Expired - Lifetime
- 2003-01-29 JP JP2003563536A patent/JP2005521663A/ja not_active Withdrawn
- 2003-01-29 NZ NZ534452A patent/NZ534452A/en not_active IP Right Cessation
- 2003-01-29 AT AT03703575T patent/ATE423552T1/de active
- 2003-01-29 EP EP08166881A patent/EP2036549B1/en not_active Expired - Lifetime
- 2003-01-29 RU RU2004122921/15A patent/RU2301673C2/ru active
- 2003-01-29 UA UA20040806416A patent/UA79445C2/uk unknown
- 2003-01-29 US US10/502,685 patent/US7759328B2/en not_active Expired - Lifetime
- 2003-01-29 AT AT08166881T patent/ATE463241T1/de active
- 2003-01-29 CN CNB038031221A patent/CN1287774C/zh not_active Expired - Lifetime
- 2003-01-29 ES ES03703575T patent/ES2321180T3/es not_active Expired - Lifetime
- 2003-01-29 WO PCT/SE2003/000156 patent/WO2003063842A1/en active Application Filing
- 2003-01-29 DE DE60326320T patent/DE60326320D1/de not_active Expired - Lifetime
- 2003-01-29 DK DK08166881.6T patent/DK2036549T3/da active
- 2003-01-29 SI SI200331805T patent/SI2036549T1/sl unknown
- 2003-01-29 KR KR1020097024298A patent/KR20090125857A/ko not_active Application Discontinuation
- 2003-01-29 KR KR1020047011787A patent/KR100947168B1/ko active IP Right Grant
- 2003-01-29 DE DE60332067T patent/DE60332067D1/de not_active Expired - Lifetime
- 2003-01-29 PT PT03703575T patent/PT1474117E/pt unknown
- 2003-01-29 EP EP03703575A patent/EP1474117B1/en not_active Revoked
- 2003-01-29 ES ES08166881T patent/ES2342509T3/es not_active Expired - Lifetime
- 2003-01-29 SI SI200331563T patent/SI1474117T1/sl unknown
-
2004
- 2004-07-21 IS IS7360A patent/IS7360A/is unknown
- 2004-07-22 IL IL163160A patent/IL163160A/en active IP Right Grant
- 2004-07-27 CO CO04071996A patent/CO5611098A2/es not_active Application Discontinuation
- 2004-07-28 MX MXPA04007295A patent/MXPA04007295A/es active IP Right Grant
- 2004-07-29 ZA ZA2004/06086A patent/ZA200406086B/en unknown
- 2004-08-19 NO NO20043458A patent/NO337006B1/no not_active IP Right Cessation
-
2009
- 2009-04-29 CY CY20091100471T patent/CY1109030T1/el unknown
- 2009-06-30 HK HK09105851.8A patent/HK1126684A1/xx not_active IP Right Cessation
-
2010
- 2010-02-26 JP JP2010041992A patent/JP5259636B2/ja not_active Expired - Lifetime
- 2010-05-28 US US12/790,196 patent/US8143239B2/en not_active Expired - Fee Related
- 2010-06-14 CY CY20101100546T patent/CY1110081T1/el unknown
-
2012
- 2012-03-05 US US13/411,939 patent/US8575137B2/en not_active Expired - Lifetime
-
2013
- 2013-04-16 IS IS9028A patent/IS2960B/is unknown
- 2013-10-18 US US14/057,548 patent/US20140286878A1/en not_active Abandoned
-
2015
- 2015-03-02 US US14/635,550 patent/US20160022703A1/en not_active Abandoned
-
2017
- 2017-02-08 US US15/427,425 patent/US10166247B2/en not_active Expired - Lifetime
-
2018
- 2018-08-22 US US16/108,368 patent/US20190216828A1/en not_active Abandoned
-
2020
- 2020-03-27 US US16/832,590 patent/US11311558B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5611098A2 (es) | Composicion para inhalacion | |
| SI2042168T1 (sl) | Inhalacijska formulacija, ki obsega fenetanolaminske derivate, za zdravljenje respiratornih bolezni | |
| AU2003264282A1 (en) | Phenethanolamine derivatives and their use in the treatment of respiratory diseases | |
| DK2156840T3 (da) | Anvendelse af mometasonfuroat til behandling af luftvejs- og lungesygdomme | |
| HRP20050579B1 (hr) | Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol | |
| EA200500328A1 (ru) | Композиция и лекарственное средство для лечения респираторных заболеваний, аллергических заболеваний, астмы и/или хронических обструктивных заболеваний легких и способ получения лекарственного средства | |
| WO2005011602A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease | |
| WO2005011613A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |